ResMed (RMD) CEO granted 33,288 stock options at $250.52

ResMed Inc. (RMD) reported an equity compensation grant to its Chairman and CEO on a Form 4.

Rhea-AI Filing Summary

ResMed Inc. (RMD) reported an equity compensation grant to its Chairman and CEO on a Form 4. On 11/24/2025, he received options to purchase 33,288 shares of ResMed common stock at an exercise price of $250.52 per share. These options first become exercisable on 11/11/2026 and vest in three equal annual installments starting on that date, aligning his incentives with longer-term company performance. Following this grant, he beneficially owns 466,223 shares of ResMed common stock held directly.

Insider Trade Summary

Grant/Award: 33,288 shares

Grant/Award 2 txns

Insider Farrell Michael J.

Role Chairman and CEO

Type	Security	Shares	Price	Value
Grant/Award	ResMed Common Stock Options	33,288	$250.52	$8.34M
holding	ResMed Common Stock	--	--	--

Holdings After Transaction: ResMed Common Stock Options — 33,288 contracts (Direct); ResMed Common Stock — 466,223 shares (Direct)

Footnotes (1)

1. F1. Represents the date on which options first become exercisable. The options vest in three equal annual installments commencing on November 11, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ResMed Inc (RMD) report on this Form 4?

ResMed Inc reported that its Chairman and CEO received stock options for 33,288 shares of ResMed common stock with an exercise price of $250.52 per share.

When do the new ResMed (RMD) CEO stock options start vesting and over what period?

The options first become exercisable on 11/11/2026 and vest in three equal annual installments starting on that date.

What is the exercise price of the stock options granted to the ResMed (RMD) CEO?

The stock options granted to the Chairman and CEO have an exercise price of $250.52 per share of ResMed common stock.

How many ResMed (RMD) shares does the reporting person own after this transaction?

After the reported option grant, the reporting person beneficially owns 466,223 shares of ResMed common stock directly.

Is the Form 4 for ResMed (RMD) filed by one or multiple reporting persons?

The Form 4 is filed by one reporting person, who is both a Director and the Chairman and CEO of ResMed Inc.

What type of derivative security is involved in this ResMed (RMD) Form 4 filing?

The filing reports stock options on ResMed common stock as the derivative securities acquired by the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/26/2025 - 03:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock								466,223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$250.52	11/24/2025		A		33,288		11/11/2026(1)	11/11/2032	ResMed Common Stock	33,288	$250.52	33,288	D

Explanation of Responses:

1. Represents the date on which options first become exercisable. The options vest in three equal annual installments commencing on November 11, 2026.

	/s/ Michael J. Rider, attorney-in-fact for Mr. Farrell	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.